Altered patterns of MDM2 and TP53 expression in human bladder cancer.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Journal of the National Cancer Institute

• Publication date

  1994-09-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/86.17.1325PMID 8064890
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA damage increases the levels of MDM2 messenger RNA in wtp53 human cells.

  1994cited by this paper
• Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors.

  1994cited by this paper
• Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.

  1994cited by this paper
• MDM2 gene amplification in metastatic osteosarcoma.

  1993cited by this paper
• High-risk human papillomavirus infections and overexpression of p53 protein as prognostic indicators in transitional cell carcinoma of the urinary bladder.

  1993cited by this paper
• Thymocyte apoptosis induced by p53-dependent and independent pathways

  1993cited by this paper
• p53 is required for radiation-induced apoptosis in mouse thymocytes

  1993cited by this paper
• Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations.

  1993cited by this paper
• Gain of function mutations in p53

  1993cited by this paper
• Role of chromosome 9 in human bladder cancer.

  1993cited by this paper
• Preliminary mapping of the deleted region of chromosome 9 in bladder cancer.

  1993cited by this paper
• p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

  1993cited by this paper
• Mapping of the p53 and mdm-2 interaction domains.

  1993cited by this paper
• p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.

  1993cited by this paper
• P53 nuclear overexpression and disease progression in ta-bladder carcinoma.

  1993cited by this paper
• The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

  1993cited by this paper
• Genetic alterations in bladder cancer.

  1993cited by this paper
• Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer

  1993cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• The mdm-2 gene is induced in response to UV light in a p53-dependent manner.

  1993cited by this paper
• Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

  1993cited by this paper
• Novel DNA binding of p53 mutants and their role in transcriptional activation.

  1993cited by this paper
• The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation.

  1992cited by this paper
• A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia.

  1992cited by this paper
• Wild-type p53 activates transcription in vitro

  1992cited by this paper
• Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein

  1992cited by this paper
• Amplification of a gene encoding a p53-associated protein in human sarcomas

  1992cited by this paper
• The transcriptional transactivation function of wild‐type p53 is inhibited by SV40 large T‐antigen and by HPV‐16 E6 oncoprotein.

  1992cited by this paper
• Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.

  1992cited by this paper
• Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer.

  1992cited by this paper
• Epidemiology of bladder cancer.

  1992cited by this paper
• Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

  1991cited by this paper
• Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line.

  1991cited by this paper
• Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct.

  1991cited by this paper
• Molecular genetic alterations in superficial and locally advanced human bladder cancer.

  1991cited by this paper
• Association of human papillomavirus types 16 and 18 E6 proteins with p53.

  1990cited by this paper
• Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

  1989cited by this paper
• Bladder cancer in relation to cigarette smoking.

  1988cited by this paper
• Demonstration of papillomavirus structural antigen in human urinary bladder neoplasia.

  1987cited by this paper
• Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression.

  1986cited by this paper
• The natural history of papillary transitional cell carcinoma of the bladder and its treatment in an unselected population on the basis of histologic grading.

  1978cited by this paper
• DNA sequencing with chain-terminating inhibitors.

  1977cited by this paper

• Association of MDM2 Overexpression in Ameloblastomas with MDM2 Amplification and BRAFV600E Expression

  2024cites this paper
• Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model

  2023cites this paper
• Diagnostic value of MDM2 RNA in situ hybridization for low-grade osteosarcoma: Consistency comparison of RNA in situ hybridization, fluorescence in situ hybridization, and immunohistochemistry

  2023cites this paper
• A p53/LINC00324 positive feedback loop suppresses tumor growth by counteracting SET-mediated transcriptional repression.

  2023cites this paper
• The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy

  2023cites this paper
• Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma.

  2021cites this paper
• A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts

  2020cites this paper
• Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.

  2020cites this paper
• In Silico Prediction of the Mode of Action of Viola odorata in Diabetes

  2020cites this paper
• A robust eleven-genes prognostic model can predict overall survival in bladder cancer patients based on ve cohorts

  2020cites this paper
• Comparison of P53 Protein Overexpression With P53 Mutation In Bladder Cancer: Clinical and Biologic Aspects

  2019cites this paper
• Landscape perspectives of tumor, EMT, and development

  2019cites this paper
• Aspects of Development and Progression of Bladder Cancer 2

  2019cites this paper
• Chapter 12 – Big Drug Design Mechanisms via Systems Biology and Big Database Mining

  2017cites this paper
• Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4th Edition Guidelines as a Molecular Insight towards Personalized Medicine

  2017cites this paper
• Tp53 and its potential therapeutic role as a target in bladder cancer

  2017cites this paper
• MicroRNA-379-5p plays a tumor-suppressive role in human bladder cancer growth and metastasis by directly targeting MDM2.

  2017cites this paper
• Classification of Bladder Cancer Patients via Penalized Linear Discriminant Analysis

  2017cites this paper
• Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.

  2016cites this paper
• The Role of MDM2 Amplification and Overexpression in Tumorigenesis.

  2016cites this paper
• Interaction between p53 codon 72 and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma

  2016cites this paper
• Serum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer

  2016cites this paper
• Biological determinants of bladder cancer gene expression subtypes

  2015cites this paper
• New and promising strategies in the management of bladder cancer.

  2015cites this paper
• Opportunities to improve clinical trial design in urothelial bladder cancer

  2015cites this paper
• Molecular Biology of Urothelial Cancer

  2015cites this paper
• p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells

  2015cites this paper
• Biomarkers in bladder cancer: translational and clinical implications.

  2014cites this paper
• Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma

  2014cites this paper
• The role of FGFR3 mutation in tumour initiation, progression and invasion of urothelial cell carcinoma in mice

  2014cites this paper
• Targeting MDM2-p53 interaction for cancer therapy: are we there yet?

  2014cites this paper
• Research progress on bladder cancer molecular genetics.

  2014cites this paper
• Transcriptome-Based Analysis of Kidney Gene Expression Changes Associated with Diabetes in OVE26 Mice, in the Presence and Absence of Losartan Treatment

  2014cites this paper
• Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden

  2014cites this paper
• Mdm 2 SNP 309 G-Variant Is Associated with Invasive Growth of Human Urinary Bladder Cancer

  2013cites this paper
• THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.

  2013cites this paper
• Mdm2 SNP309 G-Variant Is Associated with Invasive Growth of Human Urinary Bladder Cancer

  2013cites this paper
• Tissue‐based Biomarkers

  2012cites this paper
• Bladder Cancer Biology

  2012cites this paper
• Immunohistochemical Comparison of the Expression of p53 and MDM2 Proteins in Ameloblastomas and Keratocystic Odontogenic Tumors

  2011cites this paper
• Chapter 16 – Immunohistology of the Prostate, Bladder, Kidney, and Testis

  2011cites this paper
• The Emphasis of Tumor Suppressor Genes and Oncogenes in Diagnosis and Prognosis of Anaplastic Brain Tumors

  2011cites this paper
• Associations of MDM2 SNP309, Transcriptional Activity, mRNA Expression, and Survival in Stage I Non-Small-Cell Lung Cancer Patients with Wild-Type p53 Tumors

  2010cites this paper
• Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice.

  2010cites this paper
• Role of X-Linked Inhibitor of Apoptosis Protein in Therapeutic Resistance of Inflammatory Breast Cancer Cells

  2010cites this paper
• Inactivation of p53 and Pten promotes invasive bladder cancer.

  2009cites this paper
• Molecular Pathogenesis of Urothelial Carcinoma and the Development of Novel Therapeutic Strategies

  2009cites this paper
• Proteasome system of protein degradation and processing

  2009cites this paper
• Veränderungen am Protoonkogen MDM2 bei Urothelkarzinomen in Bezug auf bekannte Risikofaktoren - Relation von Umweltfaktoren und intrazellulärem Signalweg?

  2009cites this paper
• Correlation of p53, MDM2 and p14ARF protein expression in human esophageal squamous cell carcinoma

  2009cites this paper
• Bladder cancer: modeling and translation.

  2009cites this paper
• Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells.

  2009cites this paper
• Bladder cancer subtypes defined by genomic alterations

  2008cites this paper
• Molecular alterations associated with bladder cancer initiation and progression

  2008cites this paper
• Association of p73 and MDM2 Polymorphisms With the Risk of Epithelial Ovarian Cancer in Chinese Women

  2008cites this paper
• Crosstalk Between MDM2 and Akt Signaling Pathway in Oncogenesis.

  2008cites this paper
• P27 and mdm2 as molecular grading biomarkers in transitional cell carcinoma

  2008cites this paper
• Prognostic and predictive markers in radiation therapy: focus on prostate cancer.

  2008cites this paper
• Molecular pathogenesis of bladder cancer

  2008cites this paper
• A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer

  2007cites this paper
• p-Phenylenediamine induced DNA damage in SV-40 immortalized human uroepithelial cells and expression of mutant p53 and COX-2 proteins.

  2007cites this paper
• Genomic and proteomic profiles reveal the association of gelsolin to TP53 status and bladder cancer progression.

  2007cites this paper
• Molecular biology of bladder cancer

  2007cites this paper
• Targeted therapies in the management of metastatic bladder cancer

  2007cites this paper
• MOLECULAR PROFILING OF UROTHELIAL CARCINOMA

  2006cites this paper
• Chapter 14 – Immunohistology of the Prostate, Bladder, Testis and Kidney

  2006cites this paper
• The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors

  2006cites this paper
• Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

  2006cites this paper
• Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging

  2006cites this paper
• Role of MDM2 In Cell Growth Regulation

  2006cites this paper
• Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in muscle-invasive bladder cancer treated with neo-adjuvant chemotherapy followed by locoregional surgical treatment.

  2006cites this paper
• Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population

  2006cites this paper
• Clinically Significant Molecular Markers for Urologic Disease: Focus on Bladder, Kidney, and Prostate Cancer

  2006cites this paper
• Protein expression of Mdm2 and p53 in hyperplastic and neoplastic lesions of the canine circumanal gland.

  2005cites this paper
• MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy.

  2005cites this paper
• Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.

  2005cites this paper
• Alterations of G1‐S checkpoint in chordoma

  2005cites this paper
• The Prognostic Importance of E-cadherin and p53 Gene Expression in Transitional Bladder Carcinoma Patients

  2005cites this paper
• Association of low CYP 3 A activity with p 53 mutation and CYP 2 D 6 activity with Rb mutation in human bladder cancer

  2005cites this paper
• Expression of p53, mdm2 and p21 Proteins in Betel Quid and Tobacco Associated Oral Squamous Cell Carcinoma in Bangladeshi Population

  2005cites this paper
• Predictive Value of p 53 Mutations Analyzed in Bladder Washings for Progression of High-Risk Superficial Bladder Cancer 1

  2005cites this paper
• Alteration of the MDM2-p73-P14ARF pathway related to tumour progression during urinary bladder carcinogenesis.

  2004cites this paper
• The Clinical Significance of Molecular Markers to Bladder Cancer

  2004cites this paper
• p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.

  2004cites this paper
• Oligoclonality in bladder cancer: the implication for molecular therapies.

  2004cites this paper
• Molecular pathways in bladder cancer

  2004cites this paper
• FACTORES PRONÓSTICOS MOLECULARES EN CÁNCER DE VEJIGA

  2004cites this paper
• p53 Alterations and Their Relationship to SDHD Mutations in Parasympathetic Paragangliomas

  2003cites this paper
• Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1–5

  2003cites this paper
• Single‐cell immunohistochemical mutation load assay (SCIMLA) using human paraffin‐embedded tissues

  2003cites this paper
• [Bladder tumors and molecular markers. Current status and perspectives].

  2003cites this paper
• Can p53 staining be used to identify patients with aggressive superficial bladder cancer?

  2003cites this paper
• Molecular pathogenesis of urothelial bladder cancer.

  2003cites this paper
• Prognostic value of p53 and MDM2 expression in bilharziasis-associated squamous cell carcinoma of the urinary bladder.

  2003cites this paper
• Cell cycle regulatory functions of the human oncoprotein MDM2.

  2003cites this paper
• Expression of caveolin-1 and caveolin-2 in urothelial carcinoma of the urinary bladder correlates with tumor grade and squamous differentiation.

  2003cites this paper
• Lack of p53 Nuclear Immunostaining Is Not Indicative of Absence of TP53 Gene Mutations in Colorectal Adenocarcinomas

  2003cites this paper
• Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer.

  2003cites this paper
• Fragile sites and bladder cancer.

  2003cites this paper
• Prognostic value of p53 and MDM2 Expression in Bilharziasis-Associated Squamous Cell Carcinoma of the Urinary Bladder

  2003cites this paper